Result 1 - 10 of total 1808
The Chicago medical journal
2023 Volume 16, Issue 11, Page(s) 645–646
| Language | English |
|---|---|
| Publishing date | 2023-07-06 |
| Publishing country | United States |
| Document type | Journal Article |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
Bericht über eien Abschied
(Praxis PalliativeCare ; 28, Praxisbeil.)
2015
| Author's details | Maria Stahl |
|---|---|
| Series title | Praxis PalliativeCare ; 28, Praxisbeil. |
| Collection | |
| Language | German |
| Size | [14] S. |
| Publisher | Brinkmann-Meyhöfer |
| Publishing place | Hannover |
| Publishing country | Germany |
| Document type | Book |
| HBZ-ID | HT018758302 |
| Database | Catalogue ZB MED Medicine, Health |
| Shelf mark | Loan status | Location |
|---|---|---|
| Zs A 7063 -28,Praxisbeil.- | verfügbar in Königswinter | Königswinter |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
The European respiratory journal
2021 Volume 58, Issue 1
| MeSH term(s) | Child ; Cystic Fibrosis/complications ; Cystic Fibrosis/diagnosis ; Humans ; Lung/diagnostic imaging |
|---|---|
| Language | English |
| Publishing date | 2021-07-08 |
| Publishing country | England |
| Document type | Editorial ; Comment |
| ZDB-ID | 639359-7 |
| ISSN | 1399-3003 ; 0903-1936 |
| ISSN (online) | 1399-3003 |
| ISSN | 0903-1936 |
| DOI | 10.1183/13993003.00236-2021 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 2322: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 292: Show issues |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
2020 Volume 60, Issue 9, Page(s) 774–780
Abstract: Although cystic fibrosis (CF) is a multiorgan disease, the extent of CF lung disease is decisive for the course and survival of patients. The optimization of symptomatic therapies has led to a significant improvement in the life expectancy of those ... ...
| Title translation | Clinical presentation of lung disease in cystic fibrosis. |
|---|---|
| Abstract | Although cystic fibrosis (CF) is a multiorgan disease, the extent of CF lung disease is decisive for the course and survival of patients. The optimization of symptomatic therapies has led to a significant improvement in the life expectancy of those affected in recent decades. Regular monitoring of the course of CF lung disease with microbiological, pulmonary function, and imaging examinations is essential for early detection of problems and individualized therapy. With new, causal therapy options in the form of cystic fibrosis transmembrane conductance regulator (CFTR) modulators and early diagnosis through newborn screening, a further normalization of life expectancy and quality of life of CF patients can be expected. |
| MeSH term(s) | Cystic Fibrosis/complications ; Cystic Fibrosis Transmembrane Conductance Regulator ; Humans ; Lung ; Lung Diseases/diagnosis ; Lung Diseases/etiology ; Quality of Life |
| Chemical Substances | Cystic Fibrosis Transmembrane Conductance Regulator (126880-72-6) |
| Language | German |
| Publishing date | 2020-10-06 |
| Publishing country | Germany |
| Document type | Journal Article ; Review |
| ZDB-ID | 505520-9 |
| ISSN | 1432-2102 ; 0033-832X |
| ISSN (online) | 1432-2102 |
| ISSN | 0033-832X |
| DOI | 10.1007/s00117-020-00728-9 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Ue I Zs.274: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MG 106: Show issues |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
2019 Volume 19, Issue 10, Page(s) 14–18
| Language | German |
|---|---|
| Document type | Article |
| ZDB-ID | 2108287-X |
| ISSN | 1618-7687 |
| Database | Current Contents Medicine |
| Zs.A 6162: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Leitlinie - Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
(Onkopedia Leitlinien)
2022
Abstract: Ösophaguskarzinome machen in Deutschland ca. 1% aller malignen Erkrankungen und ca. 2% aller krebsbedingten Todesfälle aus. Klinisch relevant ist die Unterscheidung zwischen Plattenepithel- und Adenokarzinomen. Ca. 30-40% der Patient*innen befinden sich ... ...
| Institution | Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie Schweizerische Gesellschaft für Medizinische Onkologie Schweizerische Gesellschaft für Hämatologie Deutsche Krebsgesellschaft / Arbeitsgemeinschaft für Internistische Onkologie |
|---|---|
| Author's details | DGHO - Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V., OeGHO - Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie, SSMO/SSOM/SGMO - Schweizerische Gesellschaft für Medizinische Onkologie, SGH-SSH - Schweizerische Gesellschaft für Hämatologie/Société Suisse d'Hématologie, AIO - Arbeitsgemeinschaft für Internistische Onkologie ; Autoren: Michael Stahl, Salah-Eddin Al-Batran, Markus Borner, Ines Gockel, Lars Grenacher, Holger Hass, Dieter Köberle, Markus Möhler, Rainer Porschen, Ron Pritzkuleit, Holger Rumpold, Martin Stuschke, Marianne Sinn ; In Kooperation mit der AIO |
| Series title | Onkopedia Leitlinien |
| Abstract | Ösophaguskarzinome machen in Deutschland ca. 1% aller malignen Erkrankungen und ca. 2% aller krebsbedingten Todesfälle aus. Klinisch relevant ist die Unterscheidung zwischen Plattenepithel- und Adenokarzinomen. Ca. 30-40% der Patient*innen befinden sich bei Erstdiagnose prinzipiell in einem resektablen Stadium. Insbesondere bei Patient*innen mit einem Plattenepithelkarzinom sind häufig Komorbiditäten zu beachten mit einer daraus resultierenden eingeschränkten funktionellen Operabilität. Das 5-Jahres-Überleben mit alleiniger Resektion liegt um 20%. Multimodale Konzepte verbessern bei lokal fortgeschrittenen Tumoren die Prognose, sie können zudem einen Organerhalt ermöglichen. Nach präoperativer Chemoradiotherapie und kompletter Resektion besteht bei Patient*innen mit histologischem Tumorrest (nicht-PCR) eines Plattenepithelkarzinoms oder Adenokarzinoms (einschl. AEG 1) eine Indikation zum Einsatz einer adjuvanten Immuntherapie (unabhängig vom PD-L1 Status). Für metastasierte Plattenepithelkarzinome bleibt eine platinbasierte Chemotherapie trotz geringer Evidenz die Behandlung der Wahl. Der Einsatz von Checkpoint-Inhibitoren ist in Kombination mit Chemotherapie in der Erstlinie (PD-L1 CPS ≥ 10) und als Monotherapie (unabhängig vom PD-L1 Status) in der Zweitlinie zugelassen. Für die metastasierten Adenokarzinome des Ösophagus und des ösophago-gastralen Übergangs stehen in Analogie zum Magenkarzinom neben der kombinierten Chemotherapie auch personalisierte Therapieansätze (HER-2 positive Karzinome) und die Immuntherapie in Kombination mit Chemotherapie (PD-L1 CPS ≥ 5) zur Verfügung. |
| Subject code | 610 |
| Language | German |
| Size | 1 Online-Ressource (50 Seiten), Diagramme |
| Edition | Stand: April 2022 |
| Publisher | DGHO - Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V |
| Publishing place | Berlin |
| Publishing country | Germany |
| Document type | Book ; Online |
| Note | Open Access |
| HBZ-ID | HT021567315 |
| Database | ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
American journal of respiratory and critical care medicine
2023 Volume 208, Issue 9, Page(s) 911–913
| MeSH term(s) | Humans ; Cystic Fibrosis/drug therapy ; Cystic Fibrosis/genetics ; Tomography, X-Ray Computed ; Aminophenols/therapeutic use ; Benzodioxoles/therapeutic use ; Lung |
|---|---|
| Chemical Substances | elexacaftor (RRN67GMB0V) ; ivacaftor (1Y740ILL1Z) ; tezacaftor ; Aminophenols ; Benzodioxoles |
| Language | English |
| Publishing date | 2023-09-26 |
| Publishing country | United States |
| Document type | Editorial ; Comment |
| ZDB-ID | 1180953-x |
| ISSN | 1535-4970 ; 0003-0805 ; 1073-449X |
| ISSN (online) | 1535-4970 |
| ISSN | 0003-0805 ; 1073-449X |
| DOI | 10.1164/rccm.202309-1646ED |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Uh II Zs.80: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Innere Medizin (Heidelberg, Germany)
2024
Abstract: Background: Cystic fibrosis (CF, or mucoviscidosis) is one of the rare diseases with a fatal course and with the highest prevalence. Formerly known as a purely childhood disease, this multisystemic disease follows an autosomal recessive inheritance ... ...
| Title translation | Cystic fibrosis in childhood and adulthood. |
|---|---|
| Abstract | Background: Cystic fibrosis (CF, or mucoviscidosis) is one of the rare diseases with a fatal course and with the highest prevalence. Formerly known as a purely childhood disease, this multisystemic disease follows an autosomal recessive inheritance pattern and results in a malfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) channel, leading to the production of viscous secretions. The prognosis and outcome of CF are determined by the severity of the involvement of the lungs. Other typically affected organs include the pancreas, liver and intestines. Objective: This article reviews the clinical presentation and evolution of CF with a focus on the new era of the highly effective CFTR modulator treatment. Material and methods: An overview of the current state of knowledge on the care for CF patients is presented. Results and discussion: The introduction of the CF newborn screening, the increased understanding of the disease and the development of novel treatment options have substantially increased the quality of life and life expectancy of people with CF. As a result, more than half of CF patients in Germany are now older than 18 years of age and the complications of a chronic disease as well as organ damage due to the intensive treatment are gaining in importance. The highly effective CFTR modulator treatment results in a significant improvement in CFTR function, lung function, body mass index and quality of life and is available to approximately 90% of patients in Germany, based on the genotype. Nevertheless, further research including the development of causal treatment, e.g., gene therapy, targeting the underlying defect in the remaining 10% of CF patients, is urgently needed. Even in adult patients, CF with a mild course or a CFTR-related disease should be considered, e.g., in cases of bronchiectasis and/or recurrent abdominal complaints. |
| Language | German |
| Publishing date | 2024-05-07 |
| Publishing country | Germany |
| Document type | English Abstract ; Journal Article ; Review |
| ISSN | 2731-7099 |
| ISSN (online) | 2731-7099 |
| DOI | 10.1007/s00108-024-01717-z |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
2017 Volume 23, Issue 12, Page(s) 974
| Language | German |
|---|---|
| Document type | Article |
| ZDB-ID | 1229978-9 |
| ISSN | 0947-8965 |
| Database | Current Contents Medicine |
| Zs.A 4323: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Current hematologic malignancy reports
2024
Abstract: Purpose of review: Myelodysplastic syndromes/neoplasms (MDS) represent a diverse group of pathologically distinct diseases with varying prognoses and risks of leukemia progression. This review aims to discuss current treatment options for elderly ... ...
| Abstract | Purpose of review: Myelodysplastic syndromes/neoplasms (MDS) represent a diverse group of pathologically distinct diseases with varying prognoses and risks of leukemia progression. This review aims to discuss current treatment options for elderly patients with MDS, focusing on patients ineligible for intensive chemotherapy or allogenic hematopoietic stem cell transplantation (HSCT). The challenges associated with treatment in this population and emerging therapeutic prospects are also explored. Recent findings: Recent advancements in molecular diagnostics have enhanced risk stratification by incorporating genetic mutations, notably through the molecular International Prognostic Scoring System (IPSS-M). Lower-risk MDS (LR-MDS) treatment ranges from observation to supportive measures and erythropoiesis-stimulating agents (ESAs), with emerging therapies like luspatercept showing promise. High-risk MDS (HR-MDS) is treated with hypomethylating agents (HMAs) or allogenic HSCT, but outcomes remain poor. Elderly MDS patients, often diagnosed after 70, pose challenges in treatment decision-making. The IPSS-M aids risk stratification, guiding therapeutic choices. For LR-MDS, supportive care, ESAs, and novel agents like luspatercept are considered. Treatment of HR-MDS involves HMAs or allogenic HSCT. Emerging treatments, including oral HMAs and novel agents targeting FLT3, and IDH 1/2 mutations, show promise. Future research should refine treatment strategies for this elderly population focusing on quality-of-life improvement. |
|---|---|
| Language | English |
| Publishing date | 2024-04-18 |
| Publishing country | United States |
| Document type | Journal Article ; Review |
| ZDB-ID | 2229765-0 |
| ISSN | 1558-822X ; 1558-8211 |
| ISSN (online) | 1558-822X |
| ISSN | 1558-8211 |
| DOI | 10.1007/s11899-024-00733-y |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 6332: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.